Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:21:35 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:TAK from 2023-05-03 to 2024-05-02 - 61 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-26 08:30U:TAKNews ReleaseTakeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
2024-04-26 08:30U:TAKNews ReleaseHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
2024-04-23 07:00U:TAKNews ReleaseNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
2024-04-22 04:10U:TAKNews ReleaseTakeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
2024-04-18 19:00U:TAKNews ReleaseU.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO(TM) (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
2024-04-08 08:00U:TAKNews ReleaseTakeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
2024-03-26 19:07U:TAKNews ReleaseTakeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
2024-03-26 08:00U:TAKNews ReleaseTakeda Announces Approval of ADZYNMA(TM) Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2024-03-19 12:20U:TAKNews ReleaseTakeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG(TM) (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
2024-03-19 06:31U:TAKNews ReleaseCENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
2024-03-13 08:00U:TAKNews ReleaseTakeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
2024-02-26 23:30U:TAKNews ReleaseTakeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
2024-02-26 07:00U:TAKNews ReleaseChampioning Rare Voices on Rare Disease Day
2024-02-26 07:00U:TAKNews ReleaseChampioning Rare Voices on Rare Disease Day
2024-02-12 08:00U:TAKNews ReleaseFDA Approves Takeda ¢ € ™s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
2024-02-08 18:00U:TAKNews ReleaseTakeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
2024-02-01 01:54U:TAKNews ReleaseTakeda Announces Chief Financial Officer Succession
2024-01-29 11:10U:TAKNews ReleaseTakeda ¢ € ™s GAMMAGARD LIQUID ‚ ® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-01-29 02:00U:TAKNews ReleaseTakeda ¢ € ™s HYQVIA ‚ ® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-01-25 17:00U:TAKNews ReleaseCognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
2024-01-18 07:00U:TAKNews ReleaseTakeda Named Global Top Employer for Seventh Consecutive Year
2024-01-16 08:00U:TAKNews ReleaseU.S. FDA Approves Takeda ¢ € ™s HYQVIA ‚ ® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2023-12-21 16:00U:TAKNews ReleaseTakeda Announces China NMPA Approval of LIVTENCITY ‚ ® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
2023-12-20 07:01U:TAKNews ReleaseTakeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA ®, Treatment for Rare form of Emphysema
2023-12-20 07:01U:TAKNews ReleaseTakeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA ®, Treatment for Rare form of Emphysema
2023-12-15 08:16U:TAKNews ReleaseTakeda Receives Positive CHMP Opinion for HYQVIA ‚ ® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2023-12-05 08:00U:TAKNews ReleaseTakeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
2023-11-27 08:00U:TAKNews ReleaseTakeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
2023-11-09 15:50U:TAKNews ReleaseTakeda ¢ € ™s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2023-11-08 17:54U:TAKNews ReleaseTakeda Receives U.S. FDA Approval of FRUZAQLA ¢ „ ¢ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
2023-11-07 10:00U:TAKNews ReleaseTakeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
2023-10-26 02:00U:TAKNews ReleaseTakeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
2023-10-18 16:30U:TAKNews ReleaseEuropean Commission Approves ADCETRIS ‚ ® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
2023-10-17 19:30U:TAKNews ReleaseTakeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
2023-10-17 19:30U:TAKNews ReleaseTakeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel ‚ ® (darvadstrocel) in Complex Crohn ¢ € ™s Perianal Fistulas
2023-10-05 13:33U:TAKNews ReleaseTakeda Receives Corporate Leader Award from the Daily Bread Food Bank
2023-10-05 13:33U:TAKNews ReleaseTakeda Receives Corporate Leader Award from the Daily Bread Food Bank
2023-10-03 16:50U:TAKNews ReleaseTakeda ¢ € ™s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
2023-10-03 07:00U:TAKNews ReleaseTakeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data
2023-10-03 07:00U:TAKNews ReleaseTakeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data
2023-10-02 16:30U:TAKNews ReleaseTakeda Provides Update on EXKIVITY ‚ ® (mobocertinib)
2023-09-29 04:30U:TAKNews ReleaseHUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic ‚  Colorectal ‚  Cancer in Japan
2023-09-27 16:25U:TAKNews ReleaseU.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO ‚ ® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
2023-09-25 08:44U:TAKNews ReleaseTakeda Announces Approval of CUVITRU ¢ „ ¢ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
2023-09-20 08:00U:TAKNews ReleaseTakeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
2023-09-13 10:00U:TAKNews ReleaseTakeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
2023-09-13 08:00U:TAKNews ReleaseTakeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO ‚ ® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn ¢ € ™s Disease
2023-09-12 08:30U:TAKNews ReleasePatient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge
2023-09-12 08:30U:TAKNews ReleasePatient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge
2023-09-11 06:45U:TAKNews ReleaseTakeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
2023-07-27 02:00U:TAKNews ReleaseTakeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
2023-07-26 17:11U:TAKNews ReleaseThe New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
2023-06-25 10:45U:TAKNews ReleasePivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2023-06-20 08:45U:TAKNews ReleaseTakeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA ‚ ® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
2023-06-15 20:30U:TAKNews ReleaseHUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The ‚  Lancet
2023-06-15 20:00U:TAKNews ReleaseTakeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
2023-06-15 10:30U:TAKNews ReleaseTakeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
2023-05-26 08:00U:TAKNews ReleaseTakeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
2023-05-25 16:30U:TAKNews ReleaseTakeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
2023-05-16 21:00U:TAKNews ReleaseU.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2023-05-11 02:40U:TAKNews ReleaseTakeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook